

Content available at: <https://www.ipinnovative.com/open-access-journals>

International Journal of Pharmaceutical Chemistry and Analysis

Journal homepage: <https://www.ijpca.org/>

Original Research Article

Quantitative estimation of doxylamine succinate by zero-order derivative area under curve Spectrophotometric methods in bulk and in-tablet dosage form

Pritam S. Jain^{1*}, Ashish P. Gorle¹, Rajesh Shriram Kedar¹, Savita Mandan¹

¹R. C. Patel Institute of Pharmaceutical Education and Research, Dhule, Maharashtra, India



ARTICLE INFO

Article history:

Received 03-07-2024

Accepted 16-08-2024

Available online 30-09-2024

Keywords:

Doxylamine succinate

Distilled water

UV Spectrophotometry

AUC Spectrophotometry

pharmaceutical tablet

ABSTRACT

The purpose of this study is to establish Zero-order UV-Spectrophotometric - absorbance and Zero Order-Area under curve (AUC) methods for estimation of Doxylamine succinate in bulk and in pharmaceutical dosage form. Doxylamine succinate is Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism, distilled water was used as solvent for solubilization of Doxylamine succinate. Maximum absorption for Doxylamine succinate was found to be at wavelength 260nm when dissolved in Distilled water. The methods are based upon measurement of absorbance at 260nm and integration of area under curve for analysis of Doxylamine succinate in the wavelength range of 251.20-267.20 nm. The drug followed linearity in the concentration range of 10 - 60 μ g/mL with correlation coefficient value $r^2 > 0.99$. The proposed methods were validated for accuracy (% recovery), precision, repeatability and ruggedness, as per ICH guidelines. The proposed methods were applied for qualitative and quantitative estimation of Doxylamine succinate in tablet and results were found in good agreement with the label claimed. Developed methods can be used for routine analysis of Doxylamine succinate in bulk and pharmaceutical tablet.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Doxylamine succinate (DOX) is an Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. Doxylamine Succinate (DOX), chemically it is butanedioic acid; dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine (Figure 1). Doxylamine Succinate is an antihistamine, used to relieve symptoms of allergy, hay fever, and the common cold. This effect helps to relieve allergy, cold symptoms such as Also used in the combination with Vitamin B6 (pyridoxine) to prevent

morning sickness in pregnant women. The combined dosage forms of DOXY and PYRI are available in the market for the treatment of vomiting during pregnancy. It is official in BP and USP.

Literature survey revealed that numbers of RP-HPLC methods are available for DOX in combination with other drugs and. RP-HPLC method was also reported for the DOX. UV Spectrophotometric method like simultaneous equation method and First derivative Spectrophotometry were reported. The method was validated as per ICH guidelines.

1.1. Chemical and reagents

Doxylamine succinate was gifted by Akum Lifescience Ltd. Haridwari. All Chemicals and reagents are AR Grade and

* Corresponding author.

E-mail address: pritch79@yahoo.com (P. S. Jain).





Figure 1: The chemical structure of doxylamine succinate

purchased from Rankem Chemicals Pvt. Ltd. Mumbai and Doxylamine succinate (Doxylamine succinate USP 25mg) was purchased from Tata 1mg.

1.2. Instrument

1. Spectrophotometer: UV-2450 Shimadzu, Japan
2. Software: UV Probe 2.21
3. Sample cell: 1cm quartz cuvette
4. Lamp: Deuterium Lamp Wavelength range 200 – 400nm
5. Spectral Slit width: 1.0nm
6. Weighing Balance: Shimadzu AUX-120

2. Experimental

2.1. Preliminary solubility studies and selection of solvent

Solubility of DOX was found in Distilled Water and Ethanol. The Doxylamine succinate is completely soluble in Distilled water. So for further study Distilled water is used as a solvent.

2.2. Preparation of stock standard solution

Stock standard solution of DOX was prepared by dissolving accurately weighed 10mg of DOX into 100ml of Distilled water, to obtain concentration of 100 μ g/mL. sonicated for 5 min. The working standards were prepared by dilution of the stock standard solution.

2.3. Determination of λ max and calibration curve

A fixed volume of 1.0mL of DOX from stock solution was transferred to 10mL volumetric flask, diluted to mark with Distilled water to obtain concentration of 10 μ g/mL. The resultant solution was scanned in UV range (400-200nm) in 1.0cm cell against solvent blank. The spectrum showed an absorption maximum at 260nm.

In Method I absorbance at 260nm was considered for analysis while for Method II two wavelengths 251.20-267.20 nm were selected for determination of Area under Curve [AUC]. Zero order UV-spectrum showing maximum absorbance and AUC are shown in Figure 3.

Table 1: Optical characteristics and linearity of doxylamine succinate

Parameters	Method 1	Method 2 (AUC)
Linearity Range	10-60	10-60
Wavelength / AUC Range	260	251.20-267.20
Slope	0.0133	0.027
Intercept	0.0103	0.0082
Correlation Coefficient	0.99	0.99
LOD (μ g)	0.53811271	0.432120811
LOQ (μ g)	1.63064457	1.309457002

2.4. Method I. UV-spectrum of Doxylamine succinate in Distilled water showing λ max (260 nm)

An appropriate volume of stock solution in the range of 1ml –6mL were transferred in series of 10mL volumetric flask, volume was made up to 10mL with Distilled water to get concentration of 10–60 μ g/mL and absorbance was measured at 260nm (method I) and Zero order- AUC was recorded in between the wavelength range of 251.20-267.20 nm (Method II) against the blank. Calibration curves were prepared by plotting concentration versus absorbance and AUC as shown in Figure 3.

3. Analysis of Tablet formulation

Ten tablet were accurately weighed and average weight determined, an amount of power drug equivalent to 10 mg of Doxylamine succinate was transfer into 100 mL volumetric flask containing 100 ML of Distilled water, sonicated for 5 min. The volume was made up to the mark with same solvent and filtered through 0.45 μ m Whatman filter




Figure 2: Method II. UV-spectrum of Doxylamine succinate in Distilled water showing selection of wavelength for integration of AUC Range (251.20-267.20)




Figure 3: Linearity curve of doxylamine succinate by zero-order spectrometry

paper. A suitable volume of solution was further diluted with Distilled water to obtain concentration $30\mu\text{g/mL}$ of Doxylamine succinate for tablet assay. These sample solutions were scanned at selected wavelengths in Method I and Method-II and the results were obtained. From the respected linear regression equations, the concentrations were determined. The procedure was repeated five times and the results are shown in Table 2.




Figure 4: Linearity curve doxylamine succinate by zero order AUC spectrometry

Table 2: Analysis of doxylamine succinate tablet

	Label claim(mg)	Conc ($\mu\text{g/mL}$)	%Amount found n=5	$\pm\text{SD}$	$\pm\text{RSD}$
Method 1	25	30	101.1779	0.002915	0.704221
Method 2	25	30	99.90123460	0.005941380	7.26863263

3.1. Validation

The method was validated for accuracy, precision and ruggedness according to ICH guidelines²⁷.

3.2. Accuracy/recovery studies

To estimate the accuracy of both the proposed methods, recovery studies were executed out at 80, 100 and 120% of the test concentration as per ICH guidelines. To the pre-analyzed sample solution ($10\mu\text{g/mL}$), a known amount of drug standard was added at 80, 100 and 120% and solutions were reanalyzed by proposed methods.¹⁻⁷ The experiments were performed for three times at each level for each method. The results of the recovery studies are reported in below table.

4. Average of Three Estimates

4.1. Precision

Precision of the methods were studied as intra-day, inter-day variations and repeatability. Precision was determined by analyzing the concentration of 20, 30, and $40\mu\text{g/mL}$. To determine the degree of repeatability of the methods, statistical evaluation was carried out, and the results are reported in below table.

4.2. Repeatability

Repeatability was determined by analyzing doxylamine succinate concentration of $30\mu\text{g/mL}$ for five times and

Table 3:

% Value	Initial Amount ($\mu\text{g/mL}$)	Amount Added ($\mu\text{g/mL}$)	Method 1		Method 2	
			% Recovery	% RSD	% Recovery	% RSD
80%	40	36	101	0.68986	100.9053498	0.6151726
100%	40	40	99.19173	0.660847	101.1388889	0.5512871
120%	40	48	100.7519	0.536817	100.8333333	0.8857287

Table 4:

Concentration ($\mu\text{g/mL}$)		Intra-Day		Inter-Day	
Method 1	Method 2	% RSD		% RSD	
		Method 1	Method 2	Method 1	Method 2
20	20	1.915709	0.68918791	1.273961	0.7456714
30	30	1.692057	1.36268775	0.781495	1.61090458
40	40	1.63764	1.1310862	1.042709	0.79180726

Average of three estimates

Table 5:

Method	Concentration ($\mu\text{g/mL}$) n=5	% Amount Found	% RSD
Method 1	30	100.9774	0.577799
Method 2	30	100.419753	1.410514567

Average of five estimations

results are reported in below table.

4.3. Ruggedness

Ruggedness of the proposed method was determined by analysis of aliquots from homogenous slot by two analyst using same operational and environmental conditions and the results are reported in below table.

Table 6:

Method	Amount taken ($\mu\text{g/mL}$) n=3	% Amount found	
		Analyst 1	Analyst 2
Method 1	20	100.6391	100.7644
Method 2	20	100.20988	99.71604938

4.4. Sensitivity

The sensitivity of proposed methods was estimated in terms of estimating Detection Limit (DL) and Quantitation Limit (QL) which were calculated using formulae “DL = $3.3 \times N/B$,” and “QL = $10 \times N/B$ ” where “N” is average standard deviation of the absorbance or peak areas of the doxylamine succinate (n = 3), taken as a measure of noise, and “B” is the slope of the corresponding calibration curve.

5. Results and Discussion

In the present investigation, water-soluble drugs Doxylamine succinate in bulk and in tablet. By selecting

proper solvent. For the solubility studies, different solvent was tried but optimum solubility was achieved in Distilled water. In Method I and II, linearity of Doxylamine succinate was found to be in the range of 10 - 60 $\mu\text{g/mL}$, with correlation coefficient ($r_2 > 0.99$). Marketed brand of Tablet were analyzed. The amounts of Doxylamine succinate determined by ‘Method I’ and Method II was found to be 101.177% and 99.90 respectively. In both these methods, precision was studied as repeatability, inter and intra-day variations at three different concentrations of Doxylamine succinate and % RSD was found to be less than 2. The accuracy of method was determined by calculating mean percentage recovery.⁸⁻¹⁰ It was determined at 80, 100 and 120% level and % recovery was found to be in the range 101% - 100.90%, 99.19% - 101.13 and 100.75% 100.83% for method I and II respectively. The ruggedness of the methods was studied by two different analysts using the same operational and environmental conditions and % RSD found to be less than 2. DL and QL were found to be 0.53811271 $\mu\text{g/ml}$ and 1.63064457 $\mu\text{g/ml}$, respectively for Method I and DL and QL were found to be 0.432120811 $\mu\text{g/ml}$ and 1.309457002 $\mu\text{g/ml}$ respectively for Method II indicating adequate sensitivity of the methods.

6. Conclusion

The proposed methods for analysis of Doxylamine succinate in pharmaceutical formulations are ecofriendly; simple, precise and rapid so can be employed for routine analysis.

7. Source of Funding

None.

8. Conflict of Interest

None.

Acknowledgments

Authors are thankful to Dr. S.J. Surana, Principal, R.C. Patel Institute of Pharmaceutical Education for providing necessary facilities for this work.

References

1. and others, editor. The Indian Pharmacopoeia Commission. vol. III. 6th ed.; 2014. p. 2829.
2. and others, editor. British Pharmacopoeia Commission. vol. II; 2011. p. 1847.
3. The United States Pharmacopoeia/ The National Formulary. vol. III. Rockville, MD.; 2008. p. 3137.
4. Moffat AC, Osselton D, Widdap B, Watts J. Clark's Analysis of Drugs and Poisons. vol. II. London.: Pharmaceutical Press; 2011. p. 1309–11.
5. Sweetman SC. The Complete Drug Reference. vol. A. London.: Pharmaceutical Press; 2011. p. 2140.
6. and others, editor. British Pharmacopoeia Commission. vol. I. 10th ed. 10th; 2011. p. 769.
7. Varasala D, Konidala SK. Der pharma. *Lett.* 2015;7(1):112–8.
8. Cesar PSP, Jardim I. Simultaneous determination of clobutinol hydrochloride and doxylamine succinate from syrups by RP HPLC using a new stationary phase containing embedded urea polar groups. *Braz J Pharm Sci.* 2012;48(2):315–23.
9. Bhortake P, Lokhande RS. Validated UV-Spectrophotometric Method for the Simultaneous Estimation of Pyridoxine Hydrochloride and Doxylamine Succinate in Bulk and in Pharmaceutical Dosage Form. *Int J Pharm Sci Inven.* 2014;3(2):8–8.
10. Raja M, Samatha M, Banji D, Rao KNV, Sujitha J, Vinod D. Validated UV-Spectrophotometric Method for the Simultaneous Estimation of Pyridoxine Hydrochloride and Doxylamine Succinate in Bulk and in Pharmaceutical Dosage. *Adv J Chem Sec.* 2019;2(3):245–55.

Author biography

Pritam S. Jain, Professor

Ashish P. Gorle, Professor

Rajesh Shriram Kedar, Student

Savita Mandan, Assistant Professor

Cite this article: Jain PS, Gorle AP, Kedar RS, Mandan S. Quantitative estimation of doxylamine succinate by zero-order derivative area under curve Spectrophotometric methods in bulk and in-tablet dosage form. *Int J Pharm Chem Anal* 2024;11(3):265-269.